Dyne Therapeutics (DYN) Stock Overview
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DYN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Dyne Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.06 |
| 52 Week High | US$35.90 |
| 52 Week Low | US$6.36 |
| Beta | 1.08 |
| 1 Month Change | -3.12% |
| 3 Month Change | 49.09% |
| 1 Year Change | -59.91% |
| 3 Year Change | 2.67% |
| 5 Year Change | -29.94% |
| Change since IPO | -45.36% |
Recent News & Updates
Recent updates
Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade
Jun 18Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
Jun 17
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Mar 13We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Feb 28Dyne Therapeutics: Moving Forward On 2 Key Fronts
Jan 24We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Nov 12Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Nov 11Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
Sep 04Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12Shareholder Returns
| DYN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.7% | 5.2% | 1.2% |
| 1Y | -59.9% | -0.3% | 17.9% |
Return vs Industry: DYN underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: DYN underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| DYN volatility | |
|---|---|
| DYN Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DYN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DYN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 206 | John Cox | www.dyne-tx.com |
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc. Fundamentals Summary
| DYN fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | -US$412.89m |
| Revenue (TTM) | n/a |
Is DYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$412.89m |
| Earnings | -US$412.89m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 17.3% |
How did DYN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 05:39 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dyne Therapeutics, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Keay Nakae | Chardan Capital Markets, LLC |
| Gavin Clark-Gartner | Evercore ISI |